Isorhamnetin alleviates lipopolysaccharide-induced inflammatory responses in BV2 microglia by inactivating NF-κB, blocking the TLR4 pathway and reducing ROS generation

SHIN YOUNG KIM¹, CHENG-YUN JIN², CHEOL HONG KIM¹, YOUNG HYUN YOO³, SUNG HYUN CHOI⁴, GI-YOUNG KIM⁵, HYUN MIN YOON¹, HWAN TAE PARK⁶ and YUNG HYUN CHOI⁷,⁸

¹Department of Acupuncture and Moxibustion, Dongeui University College of Korean Medicine, Busan 47227, Republic of Korea; ²School of Pharmaceutical Sciences, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China; ³Department of Anatomy and Cell Biology, Mitochondria Hub Regulation Center, College of Medicine, Dong-A University, Busan 49201; ⁴Department of System Management, Korea Lift College, Gochang, South Gyeongsang 50141; ⁵Department of Marine Life Sciences, School of Marine Biomedical Sciences, Jeju National University, Jeju 63243; ⁶Department of Physiology, Peripheral Neuropathy Research Center, College of Medicine, Dong-A University, Busan 49201; ⁷Department of Biochemistry, Dongeui University College of Korean Medicine, Busan 47227; ⁸Anti-Aging Research Center, Dongeui University, Busan 47340, Republic of Korea

Received July 3, 2018; Accepted November 9, 2018

DOI: 10.3892/ijmm.2018.3993

Correspondence to:
Dr Hwan Tae Park, Department of Physiology, Peripheral Neuropathy Research Center, College of Medicine, Dong-A University, 32 Daesingongwon-ro, Busan 49201, Republic of Korea
E-mail: phwantae@dau.ac.kr

Dr Yung Hyun Choi, Department of Biochemistry, Dongeui University College of Korean Medicine, 62 Yangjeong-ro, Busan 47227, Republic of Korea
E-mail: choiyh@deu.ac.kr

Key words: isorhamnetin, anti-inflammatory effects, nuclear factor-κB, Toll-like receptor 4, reactive oxygen species

Abstract. Isorhamnetin, which is a flavonoid predominantly found in fruits and leaves of various plants, including Hippophae rhamnoides L. and Oenanthe javanica (Blume) DC, is known to possess various pharmacological effects. However, the anti-inflammatory potential of isorhamnetin remains poorly studied. Therefore, the present study aimed to investigate the inhibitory potential of isorhamnetin against inflammatory responses in lipopolysaccharide (LPS)-stimulated BV2 microglia. To measure the effects of isorhamnetin on inflammatory mediators and cytokines, reactive oxygen species (ROS) generation, and cytotoxicity, the following methods were used: cell viability assay, Griess assay, ELISA, reverse transcriptase-polymerase chain reaction, flow cytometry, western blotting and immunofluorescence staining. The results revealed that isorhamnetin significantly suppressed LPS-induced secretion of pro-inflammatory mediators, including nitric oxide (NO) and prostaglandin E₂, without exhibiting significant cytotoxicity. Consistent with these results, isorhamnetin inhibited LPS-stimulated expression of regulatory enzymes, including inducible NO synthase and cyclooxygenase-2 in BV2 cells. Isorhamnetin also downregulated LPS-induced production and expression of pro-inflammatory cytokines, such as tumor necrosis factor-α and interleukin-1β. The mechanism underlying the anti-inflammatory effects of isorhamnetin was subsequently evaluated; this flavonoid inhibited the nuclear factor (NF)-κB signaling pathway by disrupting degradation and phosphorylation of inhibitor-κB-α in the cytoplasm and blocking translocation of NF-κB p65 into the nucleus. In addition, isorhamnetin effectively suppressed LPS-induced expression of Toll-like receptor 4 (TLR4) and myeloid differentiation factor 88. It also suppressed the binding of LPS with TLR4 in BV2 cells. Furthermore, isorhamnetin markedly reduced LPS-induced generation of ROS in BV2 cells, thus inducing a strong antioxidative effect. Collectively, these results suggested that isorhamnetin may suppress LPS-mediated inflammatory action in BV2 microglia through inactivating the NF-κB signaling pathway, antagonizing TLR4 and eliminating ROS accumulation. Further studies are required to fully understand the anti-inflammatory effects associated with the antioxidant capacity of isorhamnetin; however, the findings of the present study suggested that isorhamnetin may have potential benefits in inhibiting the onset and treatment of neuroinflammatory diseases.

Introduction

Microglia function as macrophages in the central nervous system (CNS), and serve critical roles in brain development and maintenance. Microglial dysfunction caused by hyperac-
itivity in response to inflammatory signals is closely associated with the onset and progression of various neurodegenerative diseases by damaging brain neurons (1,2). Pathogenic endotoxins, including lipopolysaccharide (LPS), which are present in the outer membrane of Gram-negative bacteria, can induce excessive activation of microglial cells through binding to Toll-like receptor 4 (TLR4) (3,4). TLR4 ultimately activates various downstream signal transduction pathways, including the nuclear factor (NF)-κB signaling pathway, thus leading to transcription of a series of pro-inflammatory genes that induce neuroinflammation and neurodegeneration (5-7). Overactivated microglial cells stimulated by LPS can induce oxidative stress by increasing the generation of reactive oxygen species (ROS), which further aggravates the inflammatory response (8,9). Therefore, blocking excessive activation of microglia is an important tool to delay the induction and progression of numerous brain diseases.

Recent studies have reported that various natural products, including flavonoids, which are a group of naturally occurring polyphenol compounds found in plants, possess anti-inflammatory effects by blocking the activation of microglial cells (10-13). Isorhamnetin is a flavonoid present in various plants, including Hippophae rhamnoides L. (sea buckthorn) fruit and Oenanthe javanica (Blume) DC (water dropwort) leaf, which has been reported to possess various pharmacological effects. Previous studies have demonstrated that isorhamnetin can protect against inflammatory and oxidative stress responses in various in vitro and in vivo models using LPS, inflammatory cytokines and ischemic injury (14-24). The anti-inflammatory effects of isorhamnetin have been reported to be associated with inhibition of NF-κB signaling activity (20,23,25-27). In addition, its antioxidant effects can be achieved by blocking ROS production (15,21,22). However, the association between TLRs and the anti-inflammatory action of isorhamnetin has yet to be elucidated. Furthermore, to the best of our knowledge, studies on the effects of isorhamnetin on microglia have also yet to be conducted. Therefore, the present study aimed to examine the anti-inflammatory and antioxidant potency of isorhamnetin, and to determine the effects of isorhamnetin on activation of the TLR4 signaling pathway in LPS-stimulated BV2 microglia.

Materials and methods

Cell culture and LPS stimulation. The BV2 immortalized murine microglial cell line was provided by Dr Il-Whan Choi (Department of Microbiology, College of Medicine, Inje University, Busan, Korea). BV2 microglia were maintained in Dulbecco's modified Eagle's medium (DMEM; WelGENE, Inc., Gyeonggsan, Korea) containing 10% (v/v) fetal bovine serum (WelGENE, Inc.), L-glutamine (2 mM), penicillin (100 U/ml) and 100 µg/ml streptomycin (WelGENE, Inc.) at 37°C in a humidified atmosphere containing 5% CO₂ and 95% air. Isorhamnetin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich; Merck KGaA) and was adjusted to final concentrations using complete culture medium. The final DMSO concentration was <0.05% in all experiments (i.e., a non-cytotoxic range). To stimulate cells, the medium was replaced with fresh DMEM and 100 ng/ml LPS (Sigma-Aldrich Chemical Co.) was added in the presence or absence of isorhamnetin for the indicated time periods.

Assessment of cell viability. Cell viability was measured based on the formation of blue formazan, which is metabolized from colorless MTT by mitochondrial dehydrogenases, enzymes that are only active in live cells. Briefly, BV2 cells were seeded into 96-well plates at a density of 1x10⁵ cells/well. After 24 h of incubation, cells were treated with various concentrations (0, 50, 100 and 200 µM) of isorhamnetin for 24 h, or were pretreated with various concentrations of isorhamnetin for 1 h prior to LPS (100 ng/ml) treatment for 24 h at 37°C. Subsequently, the medium was removed and MTT (0.5 mg/ml; Sigma-Aldrich; Merck KGaA) was added to each well. After 3 h at 37°C, the supernatant was replaced with DMSO to dissolve blue formazan crystals in each well. After 10 min at 37°C, optical density was measured at a wavelength of 540 nm using an ELISA microplate reader (Dynex Technologies, Chantilly, VA, USA). Growth inhibition was assessed as percentage viability where vehicle (0.05% DMSO)-treated cells were taken as 100% viable (28).

Measurement of pro-inflammatory mediators and cytokines. Levels of nitric oxide (NO) production were indirectly determined by measuring the stable NO catabolite, nitrite, in the medium using the Griess reaction. Briefly, BV2 cells (5x10⁴ cells/ml) were stimulated in 24-well plates with or without various concentrations of isorhamnetin for 1 h prior to LPS (100 ng/ml) treatment for 24 h. Subsequently, the culture medium supernatant (100 µl) was mixed with the same volume of Griess reagent (Sigma-Aldrich; Merck KGaA) and was incubated at room temperature for 10 min. The optical density was then measured at 540 nm using an ELISA microplate reader; the concentration of nitrite was calculated according to a standard curve generated from known concentrations of sodium nitrite. Levels of prostaglandin E₂ (PGE₂) (cat. no. 514010; Cayman Chemical Company, Ann Arbor, MI, USA), tumor necrosis factor (TNF)-α (cat. no. MTA00B; R&D Systems, Inc., Minneapolis, MN, USA), and interleukin (IL)-1β (cat. no. MLB000C; R&D Systems, Inc.) in the culture medium were measured using commercial ELISA kits according to the manufacturer's protocols and as described previously (10). Briefly, cells were plated in 24-well plates (1.5x10⁵ cells/well) and pretreated with various concentrations of isorhamnetin for 1 h prior to treatment with 100 ng/ml LPS for 24 h. A 100-ml aliquot of the conditioned medium was collected to determine PGE₂, TNF-α and IL-1β concentrations by ELISA, according to the recommended procedures. The cells were also treated with ISO (200 µM) alone or in combination with 15 µM ethyl-(6R)-6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate (CLI-095; Invivogen Europe, Toulouse, France), a TLR4 antagonist, for 1 h prior to treatment with LPS for 24 h.

RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR). BV2 cells were pretreated with various concentrations of isorhamnetin for 1 h, followed by treatment with 100 ng/ml LPS for 24 h. Total RNA was isolated from the cells using TRIZol® reagent (Invitrogen; Thermofisher Scientific, Inc., Waltham, MA, USA), according to the manu-
manufacturer's protocol, and RNA levels were quantified. For mRNA expression analysis, cDNA was synthesized from 1 μg total RNA using AccuPower® RT PreMix (Bioneer Corporation, Daejeon, Korea) containing Moloney murine leukemia virus reverse transcriptase, according to the manufacturer's protocol. The PCR reactions were performed using AccuPower® PCR PreMix (Bioneer Corporation) at 94°C for 5 min, followed by 27 cycles at 94°C for 30 sec, annealing [inducible nitric oxide synthase (iNOS), 52°C; cyclooxygenase (COX)-2, 57°C; TNF-α, 57°C; IL-1β, 57°C; and GAPDH, 62°C] for 30 sec and 72°C for 30 sec, followed by a final extension step at 72°C for 5 min. After amplification, the PCR products were separated by 1% agarose gel electrophoresis and were visualized using ethidium bromide (Sigma-Aldrich; Merck KGaA) staining. GAPDH was used as an internal control. Bands were semi-quantified using ImageJ (version 1.46; National Institutes of Health, Bethesda, MD, USA), were normalized to GAPDH and the ratio was determined. The PCR primers were as follows: iNOS forward, 5'-ATGTCCGAAAGCACAATCACC-3' and reverse, 5'-TAA TTGCAGGAATGAGTTG-3'; COX-2 forward, 5'-CAGC AAATCCTTGCTGTCC-3' and reverse, 5'-TGGGGAAC AATGCAACAC-3'; TNF-α forward, 5'-TCTCATCAGTT CTATGCCC-3' and reverse, 5'-GGGAGTAGACAA GGTACAC-3'; IL-1β forward, 5'-GGGCCGCTTCTCAAAA CTTTGG-3' and reverse, 5'-GCTTGGGTGAACACACTC TCC-3' and GAPDH forward, 5'-AGGCCGGTGCTGAGTA TGTC-3' and reverse, 5'-TGCCCTGCTTCACACCTTCT-3'.

Protein isolation and western blot analysis. BV2 cells were pretreated with various concentrations of isorhamnetin for 1 h, followed by treatment with 100 ng/ml LPS for 24 h. Alternatively, cells were treated with 100 ng/ml LPS for various durations. The cells were collected and cellular proteins were prepared using lysis buffer [25 mM Tris-Cl (pH 7.5), 250 mM NaCl, 5 mM ethylenediaminetetraacetic acid (EDTA), 1% Nonidet-P40, 1 mM phenylmethylsulfonyl fluoride and 5 mM dithiothreitol], as described previously (29). Cytosolic and nuclear proteins were isolated separately using an NE-PER Nuclear and Cytoplasmic Extraction Reagents kit (Pierce; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. The insoluble materials were discarded by centrifugation at 13,000 x g for 20 min at 4°C. The protein concentrations in the cell lysates were determined using a detergent-compatible protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA), according to the manufacturer's protocol. For western blotting, equal amounts of protein (50 μg) were separated by 8-10% SDS-PAGE and were transferred onto polyvinylidene difluoride membranes (Schleicher and Schuell Bioscience, Inc., Keene, NH, USA). Subsequently, these membranes were blocked with 5% non-fat dry milk/Tris-buffered saline containing 0.1% Triton X-100 (TBST) for 1 h at 25°C (room temperature) and were incubated with specific primary antibodies (Table I) at 4°C overnight. After washing membranes with TBST, they were incubated with appropriate horseradish-peroxidase (HRP)-conjugated secondary antibodies [1:500; cat. no. sc 2004, goat anti-rabbit immunoglobulin (IgG)-HRP; sc 2005, goat anti-mouse IgG-HRP; Santa Cruz Biotechnology, Inc., Dallas, TX, USA] for 2 h at 25°C. Protein bands were detected using an enhanced chemiluminescence kit (GE Healthcare, Chicago, IL, USA), according to the manufacturer's protocol. The immunoreactive bands were detected and exposed to X-ray film. Images of western blotting were also analyzed using ImageJ.

Immunofluorescence staining for nuclear translocation of NF-κB and formation of LPS/TLR4 complexes. After cells (5x10⁵ cells/ml) were pretreated with or without 200 μM isorhamnetin for 30 min, they were treated with 100 ng/ml LPS for 24 h. The cells were then washed twice with PBS, fixed in 3.7% paraformaldehyde for 15 min at 25°C, permeabilized with 0.2% Triton X-100 in PBS for 15 min, and blocked for 10 min at 20°C with PBS containing 5% bovine serum albumin (Sigma-Aldrich; Merck KGaA). The cells were then incubated with a primary antibody against NF-κB p65 (dilution, 1:100; cat. no. sc-71675; Santa Cruz Biotechnology, Inc.) at 4°C overnight, followed by incubation with a fluorescein-conjugated anti-mouse immunoglobulin G secondary antibody (dilution, 1:100; cat. no. sc-62-6511; Molecular Probes; Thermo Fisher Scientific, Inc.) for 6 h, in order to analyze the formation of LPS/TLR4 complexes. Fixed cells were also incubated with anti-TLR4 antibody (1:100; cat. no. ab8376; Abcam, Cambridge, UK) at 4°C for 90 min and were then incubated with AF 594-conjugated secondary antibody (1:100; cat. no. A-11032; Invitrogen; Thermo Fisher Scientific, Inc.) at room temperature for 1 h. Nuclei were sequentially stained with DAPI (Sigma-Aldrich; Merck KGaA) solution (2.5 μg/ml). Slides were mounted and fluorescence images were captured under a fluorescence microscope (Zeiss AG, Oberkochen, Germany).

Measurement of TLR4 expression on the cell surface. To investigate the effects of isorhamnetin on TLR4 expression on the cell surface, BV2 cells were pretreated with or without 200 μM isorhamnetin for 30 min, followed by treatment with 100 ng/ml AF-LPS for 6 h. Following treatment, cells (5x10⁵ cells/ml) were washed twice with PBS, harvested with 0.005% EDTA and analyzed by flow cytometry. AF 488 was excited using 488 argon-ion laser and detected on channel FL1 using a 530 nm emission filter. Fluorescence emission of samples was recorded by flow cytometry (BD Biosciences, San Jose, CA, USA), as previously described (30).

Detection of intracellular ROS levels. Production of intracellular ROS was monitored using 5,6-carboxy-2′,7′-dichlorofluorescin diacetate (DCF-DA; Sigma-Aldrich; Merck KGaA), which is a cell-permeable fluorogenic probe. Briefly, cells were treated with 100 ng/ml LPS for the indicated time periods, or were pretreated with 200 μM isorhamnetin or 10 mM N-acetyl cysteine (NAC; Sigma-Aldrich; Merck KGaA) for 1 h followed by stimulation with or without 100 ng/ml LPS for 1 h. These cells (5x10⁵ cells/ml) were harvested and stained with 10 μM DCF-DA in the dark at 37°C for 15 min. After rinsing twice with PBS, cells were immediately analyzed by flow cytometry with an excitation wavelength of 480 nm and an emission wavelength of 525 nm. To observe the degree of ROS production by fluorescence microscopy, the coverslips were
Isorhamnetin suppresses LPS-induced pro-inflammatory mediators and cytokines production in BV2 microglial cells. To determine the inhibitory effects of isorhamnetin on LPS-induced production of NO and PGE\(_2\), which are pro-inflammatory mediators, BV2 cells were pretreated with various concentrations of isorhamnetin for 1 h and were then stimulated with or without 100 ng/ml LPS for 24 h. Levels of NO and PGE\(_2\) in culture supernatants were determined using the Griess reaction assay and ELISA, respectively. As shown in Fig. 1A and B, LPS stimulation alone markedly increased NO and PGE\(_2\) production, as compared with in cells that were not stimulated by LPS. Conversely, isorhamnetin significantly inhibited LPS-induced secretion of NO and PGE\(_2\) in BV2 cells in a concentration-dependent manner. The effects of isorhamnetin on the production of pro-inflammatory cytokines, including TNF-\(\alpha\) and IL-1\(\beta\), were also detected in LPS-stimulated BV2 cells. According to the results of ELISA, as shown in Fig. 1C and D, the production of these two cytokines was significantly increased in the culture medium of LPS-stimulated BV2 cells; however, isorhamnetin treatment decreased the production of these cytokines in a concentration-dependent manner.

Statistical analysis. Statistical analysis was conducted using GraphPad Prism version 6.02 (GraphPad Software, Inc., La Jolla, CA, USA). All data were collected from at least three independent experiments and are presented as the means ± standard deviation. One-way analysis of variance with Tukey’s multiple comparison post hoc test was performed to analyze the data. P<0.05 was considered to indicate a statistically significant difference.

Results

Isorhamnetin attenuates LPS-induced iNOS, COX-2 and cytokine expression in BV2 microglial cells. The present study aimed to determine whether the inhibitory effects of isorhamnetin on NO and PGE\(_2\) production were associated with regulation of iNOS and COX-2 expression. As shown in Fig. 2, isorhamnetin inhibited the mRNA and protein expression levels of iNOS and COX-2 in LPS-stimulated BV2 cells in a concentration-dependent manner. In addition, isorhamnetin inhibited LPS-induced increased expression of TNF-\(\alpha\) and IL-1\(\beta\) in a concentration-dependent manner (Fig. 2). These findings indicated that isorhamnetin may suppress NO, PGE\(_2\) and cytokine production by reducing the expression of their encoding genes.

Effect of isorhamnetin on the viability of BV2 microglial cells. The MTT assay was performed to investigate whether the inhibitory effects of isorhamnetin on production of pro-inflammatory mediators and cytokines were caused by cytotoxicity. As shown in Fig. 3, the survival rate of BV2 cells was not significantly affected by treatment with ≥200 \(\mu\)M isorhamnetin alone for 24 h. In addition, no significant alteration in survival rate was detected in BV2 cells treated with ≥200 \(\mu\)M isorhamnetin, even in the presence of 100 ng/ml LPS.

Table I. List of antibodies used for western blot analysis in the present study.

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Dilution</th>
<th>Product no.</th>
<th>Species of origin</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>iNOS</td>
<td>1:1,000</td>
<td>610328</td>
<td>Rabbit polyclonal</td>
<td>BD Transduction Laboratories; BD Biosciences, San Jose, CA, USA</td>
</tr>
<tr>
<td>COX-2</td>
<td>1:500</td>
<td>160126</td>
<td>Rabbit polyclonal</td>
<td>Cayman Chemical Company, Ann Arbor, MI, USA</td>
</tr>
<tr>
<td>IL-1(\beta)</td>
<td>1:1,000</td>
<td>sc-7884</td>
<td>Rabbit polyclonal</td>
<td>Santa Cruz Biotechnology, Inc., Dallas, TX, USA</td>
</tr>
<tr>
<td>TNF-(\alpha)</td>
<td>1:1,000</td>
<td>3707S</td>
<td>Rabbit polyclonal</td>
<td>Cell Signaling Technology, Inc., Danvers, MA, USA</td>
</tr>
<tr>
<td>NF-(\kappa)B p65</td>
<td>1:1,000</td>
<td>sc-71675</td>
<td>Mouse monoclonal</td>
<td>Santa Cruz Biotechnology, Inc.</td>
</tr>
<tr>
<td>IkB(\alpha)</td>
<td>1:1,000</td>
<td>sc-371</td>
<td>Rabbit polyclonal</td>
<td>Santa Cruz Biotechnology, Inc.</td>
</tr>
<tr>
<td>p-IkB(\alpha)</td>
<td>1:1,000</td>
<td>sc-8404</td>
<td>Mouse monoclonal</td>
<td>Santa Cruz Biotechnology, Inc.</td>
</tr>
<tr>
<td>TLR4</td>
<td>1:1,000</td>
<td>ab53629</td>
<td>Goat polyclonal</td>
<td>Abcam, Cambridge, MA, USA</td>
</tr>
<tr>
<td>Myd88</td>
<td>1:1,000</td>
<td>ab2064</td>
<td>Rabbit polyclonal</td>
<td>Abcam</td>
</tr>
<tr>
<td>Lamin B</td>
<td>1:1,000</td>
<td>sc-6216</td>
<td>Goat polyclonal</td>
<td>Santa Cruz Biotechnology, Inc.</td>
</tr>
<tr>
<td>Actin</td>
<td>1:1,000</td>
<td>sc-1615</td>
<td>Goat polyclonal</td>
<td>Santa Cruz Biotechnology, Inc.</td>
</tr>
</tbody>
</table>

COX-2, cyclooxygenase-2; IkB-\(\alpha\), inhibitor \(\kappa\)B-\(\alpha\); IL-1, interleukin-1; iNOS, inducible nitric oxide synthase; Myd88, myeloid differentiation factor 88; NF-\(\kappa\)B, nuclear factor-\(\kappa\)B; p, phosphorylated; TNF-\(\alpha\), tumor necrosis factor-\(\alpha\); TLR4, Toll-like receptor 4.
The present study aimed to determine whether isorhamnetin could attenuate LPS-induced activation of NF-κB in BV2 cells. Immunoblotting data using cytoplasmic and nuclear extracts revealed that pretreatment with isorhamnetin inhibited nuclear accumulation of NF-κB p65 subunits in LPS-stimulated BV2 cells. In addition, isorhamnetin attenuated the LPS-induced inhibition of total IκBα protein expression and reduced phosphorylation of IκBα (Fig. 4A and B). Consistent with these results, immunocytochemical analysis indicated that the fluorescence intensity of NF-κB p65 in the nucleus was increased in LPS-stimulated cells. However, LPS-mediated nuclear translocation of NF-κB was considerably blocked by pretreatment with isorhamnetin (Fig. 4C), thus indicating that isorhamnetin could attenuate transcriptional activation of NF-κB.

Isorhamnetin inhibits LPS-induced TLR4 and Myd88 expression in BV2 microglial cells. To determine whether the anti-inflammatory effects of isorhamnetin were associated with blockade of the TLR signaling pathway, the expression levels of TLR4 and myeloid differentiation factor 88 (Myd88) were investigated (Fig. 5). The results of immunoblotting revealed that protein expression levels of TLR4 and Myd88 were markedly increased by LPS treatment in a time-dependent manner (Fig. 5A and C). However, when cells were pretreated with isorhamnetin, the LPS-induced increase in TLR4 and Myd88 expression was inhibited in a concentration-dependent manner (Fig. 5B and D).

Isorhamnetin blocks LPS-mediated interaction between LPS and TLR4 in BV2 microglial cells. The present study assessed whether isorhamnetin could inhibit the interaction between LPS and TLR4 on the surface of LPS-treated BV2 cells. As shown in Fig. 6A and B, fluorescence of LPS and TLR4 was observed outside the cell membrane in BV2 cells treated with AF-LPS. However, the fluorescence intensity of TLR4 and the binding activity of LPS on the cell surface were markedly attenuated in BV2 cells treated with LPS in the presence of isorhamnetin.

Interception of TLR4 signaling increases the anti-inflammatory efficacy of isorhamnetin on BV2 microglial cells. To further determine whether blockade of TLR4 signaling is mediated by the anti-inflammatory action of isorhamnetin, the present study examined the effects of the TLR4 antagonist, CLI-095, on isorhamnetin-induced inhibition of inflammatory mediators. As shown in Fig. 7A and B, CLI-095 significantly reduced the production of LPS-induced inflammatory mediators, such as NO and PGE₂. Furthermore, cotreatment with isorhamnetin and CLI-095 synergistically inhibited LPS-induced production of NO and PGE₂ and blocked the transcription of corresponding genes (Fig. 7C and D). These results suggested that the inhibitory effects of isorhamnetin on LPS-induced inflammation may be due to suppression of the TLR4-mediated NF-κB signaling pathway in BV2 microglia.

Isorhamnetin reduces LPS-induced ROS generation in BV2 microglial cells. The present study also examined the effects of isorhamnetin on LPS-induced ROS production, in order to investigate the antioxidant potential of isorhamnetin. Flow cytometry using the fluorescent probe DCF-DA revealed that the levels of ROS were gradually increased following treatment with LPS, peaking at 1 h; thereafter, ROS levels were decreased (Fig. 8A). Conversely, treatment with isorhamnetin alone did not induce ROS generation. Pretreatment with isorhamnetin effectively attenuated the levels of ROS released by LPS.
KIM et al: ANTI-INFLAMMATORY EFFECTS OF ISORHAMNETIN ON LPS-STIMULATED BV2 MICROGLIA

The inhibitory effects of isorhamnetin on ROS production were also observed under fluorescence microscopy (Fig. 8C). In NAC-pretreated cells, which were used as a positive control, the production of LPS-stimulated ROS was completely blocked. These findings indicated that isorhamnetin had a strong ROS-scavenging effect.

Discussion

The results of the present study demonstrated that isorhamnetin inhibited LPS-induced inflammatory signaling in BV2 microglia, a brain microglial cell line. Similar to the results of previous studies using macrophage and gingival fibroblast models (14,31), the present results indicated that isorhamnetin could significantly inhibit the increased production of NO and PGE₂ by LPS, in the absence of cytotoxicity, which was associated with suppression of iNOS and COX-2 expression, respectively. In addition, isorhamnetin reduced the release of TNF-α and IL-1β by blocking their expression in LPS-stimulated microglial cells; these findings are also similar to the results of previous studies (17,26). These results suggested that isorhamnetin may improve the inflammatory response by inhibiting the expression of genes that regulate the production of pro-inflammatory factors.

NF-κB is a key transcription factor that increases the expression of pro-inflammatory enzymes and cytokines only...
if it has migrated to the nucleus. NF-κB is usually located in the cytoplasm in association with IκBα. When IκBα is phosphorylated and degraded, NF-κB is isolated and translocated to the nucleus (5-7). Therefore, this study aimed to determine whether isorhamnetin could inhibit LPS-induced degradation and phosphorylation of IκBα and nuclear translocation.
of NF-κB. The results indicated that isorhamnetin could effectively block nuclear expression of NF-κB (p65), and the degradation and phosphorylation of IκBα in LPS-stimulated BV2 microglial cells. These results suggested that isorhamnetin...
may reduce the expression and production of pro-inflammatory mediators and cytokines by inhibiting the NF-κB pathway in LPS-stimulated BV2 microglia. This is in agreement with previous results observed in LPS-stimulated macrophages and human umbilical vein endothelial cells (20,26,27).

Immune cells, including microglia, can recognize pathogen-associated molecular patterns through TLR pattern recognition receptors, which are expressed on the cell surface. Among various TLRs, TLR4 is known to recruit adapter molecules, including MyD88, LPS-binding protein and differentiation cluster co-receptor, when immune cells are activated by LPS (1,2). Upon activation of TLR4 by LPS, the TLR4-MyD88-mediated signal can induce activation of mitogen-activated protein kinases (MAPKs), which eventually promote the activation of NF-κB signaling, resulting in the production of pro-inflammatory mediators and cytokines (4,32). According to the results of Yang et al (20), isorhamnetin can significantly inhibit LPS-mediated activation of the MAPK c-Jun N-terminal kinase in a macrophage model. The present study revealed that isorhamnetin suppressed LPS-induced expression of TLR4 and MyD88, and reduced the binding of TLR4 to LPS. These findings indicated that isorhamnetin may inhibit the expression of pro-inflammatory enzymes and cytokines by blocking the TLR4 signaling pathway, which is the early stage of intracellular signaling in LPS-stimulated cells. This finding demonstrated that isorhamnetin attenuated onset of the LPS-mediated intracellular signaling pathway by suppressing activation of NF-κB and inhibiting the binding of LPS to TLR4 in microglial cells. Therefore, isorhamnetin may to inhibit NF-κB and MAPK signaling pathways by exhibiting antagonistic effects on the binding of LPS to TLR4 in BV2 microglial cells.

Alongside inflammatory insults, oxidative stress is another major cause of CNS damage. Low levels of ROS serve an important role as signaling molecules that regulate the immune response to pathogens; however, overproduction of ROS contributes to neurotoxicity (8,33-35). Previous studies have reported that the LPS-induced inflammatory response in microglia is directly associated with increased ROS production and that inhibition of the inflammatory response is associated with blocking ROS production (14,32,36,37). TLR4 signaling-mediated generation of ROS by LPS accelerates the inflammatory response by activating downstream signaling cascades containing NF-κB (38-40). Therefore, inhibiting ROS production is an important strategy to suppress inflammatory responses and oxidative stress. Previous studies using various research models have demonstrated that isorhamnetin possesses strong antioxidant efficacy. For example, the beneficial effects of isorhamnetin on LPS-induced acute lung injury and collagen-induced arthritis mouse models are directly associated with its antioxidant effects (18,41). In addition, the protective effects of isorhamnetin on oxidative stress-induced DNA damage and apoptosis are associated with blocking of ROS production (22,26,42). These results are in agreement with the antioxidant efficacy of isorhamnetin observed in the present study, indicating that isorhamnetin may effectively block the production of excessive ROS induced by LPS. To the best of our knowledge, the present study is the first to report on the inhibitory effects of isorhamnetin on ROS production in microglia; however, additional studies are required to determine the direct linkage between ROS production blockade and anti-inflammatory efficacy.

In conclusion, the present study demonstrated that isorhamnetin exerted potent anti-inflammatory effects on BV2...
microglial cells. In LPS-stimulated BV2 cells, isorhamnetin was able to reduce the production of pro-inflammatory mediators and cytokines, which was associated with decreased expression of their regulatory genes via the suppression of NF-κB activity. Furthermore, isorhamnetin could block early intracellular signaling cascades by antagonizing TLR4 or suppressing ROS accumulation. Although the results of the current study may provide partial understanding of the mechanism underlying the anti-inflammatory effects of isorhamnetin, further studies are required to assess the mechanical role of isorhamnetin in various oxidative stress- and inflammation-mediated diseases.

Acknowledgements

Not applicable.

Funding

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) grant funded by the Korean government (grant nos. 2018R1A2B2005705 and 2016R1A5A2007009).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

SYK, HTP and YHC contributed to the conception and design of the experiment. SYK, CYJ, CHK, YHY and GYK performed all experiments and verified the analytical data. HMY and SHC contributed to the statistical analysis and helped interpret the results. YHC supervised the experiments in discussion with SYK, HTP, YHC, CYJ, CHK, YHY and GYK wrote the manuscript. All authors discussed the final results and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


